Baker Brothers Life Sciences Capital (GP), LLC
CIK 1307729 · last filed 2012-02-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INCY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
21ST FLOOR
NEW YORK, NY 10065
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 7,639,436 | — | — | $173.92M | 11 | 2012-02-23 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 4,922,226 | — | — | $44.72M | 1 | 2012-02-03 |
| INCY | Director | 12,213,272 | $115.81 | $1.41B | $232.64M | 16 | 2012-01-17 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 5,077,676 | — | — | $0 | 1 | 2012-01-09 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 8,011,759 | — | — | $51.49M | 5 | 2011-08-25 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 6,112,357 | — | — | $0 | 1 | 2011-07-05 |
| BCRX | 10%+ Owner | 3,841,124 | $7.99 | $30.67M | $0 | 1 | 2011-07-05 |
| Seagen Inc. (SGEN) Delisted | Director | 11,119,820 | $228.74 | $2.54B | -$16.96M | 4 | 2010-05-27 |
| RPRX | 10%+ Owner | 1,345,866 | $65.00 | $87.47M | $1.78M | 1 | 2010-04-28 |
| Aceragen, Inc. (IDRA) Delisted | 10%+ Owner | 3,218 | $7.22 | $23.3K | -$8.70M | 6 | 2008-07-30 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 8,002,776 | — | — | $63.07M | 3 | 2008-05-27 |
| NEUROGEN CORP (NRGN) Delisted | Director | — | — | — | $0 | 1 | 2008-04-15 |
| TAPESTRY PHARMACEUTICALS, INC (TPPH) Delisted | 10%+ Owner | 1,821,429 | — | — | -$7.7K | 1 | 2008-04-08 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 1,004,905 | — | — | -$8.69M | 6 | 2007-12-07 |
Recent Filings · Page 6 of 7
62 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-11-16 | INCY | Buy (P) | +674,912 | $5.73M | EDGAR |
| 2007-11-13 | INCY | Buy (P) | +1,387,546 | $11.22M | EDGAR |
| 2007-11-09 | VIROPHARMA INC (VPHM) Delisted | Buy (P) | +2,480,802 | $18.43M | EDGAR |
| 2007-11-05 | Aceragen, Inc. (IDP) Delisted | Sell (S) | −133,323 | -$1.57M | EDGAR |
| 2007-10-31 | Aceragen, Inc. (IDP) Delisted | Sell (S) | −273,966 | -$3.32M | EDGAR |
| 2007-08-03 | INCY | Buy (P) | +903,722 | $4.43M | EDGAR |
| 2007-06-22 | Aceragen, Inc. (IDP) Delisted | Mixed | — | -$875 | EDGAR |
| 2007-05-22 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +2,122,374 | $32.90M | EDGAR |
| 2007-03-13 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +505,680 | $9.24M | EDGAR |
| 2007-02-16 | Seagen Inc. (SGEN) Delisted | Mixed | −2,024,376 | -$41.85M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.